Inclusion Criteria:

• * female patients based on biological sex
• * 18 to 85 years of age
• * diagnosis of primary, invasive, non-metastatic, stages I-III breast cancer
• * completed chemotherapy for breast cancer (anthracycline, alkylating agent and/or taxane) more than 6 months but less than 18 months prior to study enrollment. Adjuvant endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy, and bisphosphonates are allowed within 6 months of study enrollment and during study participation
• * absence of contraindications to exercise or to participate in study
• * study clinician approval

Exclusion Criteria:

• * do not meet inclusion criteria
• * scheduled to receive surgery or radiation therapy during the intervention period
• * any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent)
• * lymphedema stage ≥2 prior to study enrollment
• * are pregnant
• * current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)
• * consistent participation over the past 6 months in moderate-intensity aerobic exercise training for ≥150 min/week